Abstracts Archive - Page 619 of 2607 - ACR Meeting Abstracts

Abstract Number: 2038 • ACR Convergence 2022
Single Cell RNA Sequencing Points to a Role for Fibroblasts Early in Salivary Gland Dysfunction in Primary Sjögren’s Syndrome
Sarah Pringle¹, Fred Spijkervet¹, Arjan Vissink², Hendrika Bootsma¹ and Frans Kroese¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²UMCG, Leek, Netherlands
Background/Purpose: Salivary gland (SG) dysfunction is commonly associated with the autoimmune disease primary Sjögren's syndrome (pSS). Whilst the more advanced stages of the disease are…
Abstract Number: 2048 • ACR Convergence 2022
Serology Driven Pulmonary Phenotype Characterization of Sjögren Syndrome-associated Interstitial Lung Disease: A Monocentric Cohort Study
Gaetano La Rocca¹, Francesco Ferro², Giovanni Fulvio³, Silvia Fonzetti⁴, Inmaculada Concepción Navarro García⁵, Elena Elefante⁶, Chiara Romei⁷, Marta Mosca⁶ and Chiara Baldini³, ¹University of Pisa, Rheumatology Unit, Palermo, Palermo, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³University of Pisa, Pisa, Pisa, Italy, ⁴Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, ⁵Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁶University of Pisa, Pisa, Italy, ⁷University of Pisa, Rheumatology Unit, Pisa, Italy
Background/Purpose: Interstitial lung disease (ILD) is a relatively frequent manifestation of Sjögren's Syndrome (pSS), potentially presenting with a wide spectrum of clinical-radiological characteristics. Anti-Ro52 autoantibodies…
Abstract Number: 2053 • ACR Convergence 2022
Current State and Completeness of Reporting Clinical Prediction Models Using Machine Learning in Systemic Lupus Erythematosus: A Systematic Review
Claudia Mendoza-Pinto¹, Ivet Etchegaray-Morales², Pamela Munguía-Realpozo², David Angel Osorio-Peña², Socorro Méndez-Martínez¹ and Mario Garcia-Carrasco², ¹Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Background/Purpose: There is increased interest in machine learning (ML)-based prediction models in systemic lupus erythematosus (SLE). We made a systematic review of adherence in diagnostic…
Abstract Number: 1979 • ACR Convergence 2022
Tc99m Tilmanocept Imaging Can Differentiate the Fibroid Pathotype of Rheumatoid Arthritis from Non-Fibroid Pathotypes in Patients
Costantino Pitzalis¹, rebecca hands², Swamy Venuturupalli³, Ami Ben-artzi⁴, Eric Ruderman⁵, Harris Perlman⁶, Arthur Mandelin⁵, Mara Leach⁷, Addison Hasselbach⁷, Bonnie Abbruzzese⁷, Rachael Hershey⁷, Beth Potter⁷, Jessica Fitzpatrick⁷, Aaron Thornton⁷, Michael Blue⁷, Jonathan Graf⁸, David Ralph⁷ and Michael Rosol⁷, ¹Queen Mary University of London, London, United Kingdom, ²William Harvey Research Institute, London, United Kingdom, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University, Chicago, IL, ⁷Navidea Biopharmaceuticals, Dublin, OH, ⁸Ucsf, San Francisco, CA
Background/Purpose: The primary objective of this study is to assess the relationship between joint-specific Tc99m tilmanocept (TIL) uptake values and the pathobiology of RA-involved joint…
Abstract Number: 2041 • ACR Convergence 2022
Single Cell Atlas of Minor Salivary Glands Reveals Key Differential Cellular and Functional Players in Sjögren’s and Sicca Syndrome
SABA NAYAR¹, Jason D. turner¹, Saba Asam¹, Charlotte G. Smith¹, Serena Colfrancesco², Ana Teodósio¹, Joe Flint¹, David H Gardner¹, Professor Simon Bowman³, Adam Croft¹, Andrew Filer¹, Benjamin A. Fisher¹, Christopher Buckley⁴ and Francesca Barone⁵, ¹University of Birmingham, Birmingham, United Kingdom, ²University of Rome, Rome, Italy, ³University Hospitals Birmingham, Birmingham, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom, ⁵University of Birmingham, Needham, MA
Background/Purpose: Sjögren's syndrome (SjS) shares a series of symptoms with non-SjS Sicca syndrome, a salivary gland disease characterised by glandular dysfunction and dryness. However, unlike…
Abstract Number: 1929 • ACR Convergence 2022
Outcomes and Safety of Anakinra for the Treatment of Multisystem Inflammatory Syndrome in Children
Dizon Brian¹, Christopher Redmond², Emily Gotschlich³, Sangeeta Sule⁴, Tova Ronis⁴, Kathleen Vazzana⁵, Matthew Sherman⁶, Rachael Connor⁷, Abigail Bosk⁴, Niti Dham⁴, Ashraf Harahsheh⁴, Elizabeth Wells⁴, Roberta DeBiasi⁴ and Hemalatha Srinivasalu⁴, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institutes of Health, Rockville, MD, ³FDA, Washington, DC, ⁴Children's National Hospital, Washington, DC, ⁵Arnold Palmer Hospital for Children, Orlando, FL, ⁶Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH); Children’s National Hospital, Washington, DC, ⁷Children's National Medical Center, Washington, DC
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a clinical entity distinct from primary COVID-19 infection that resembles Kawasaki disease (KD) and toxic shock syndrome.…
Abstract Number: 2050 • ACR Convergence 2022
Stratification on Baseline Interferon Scores and Use of CRESS to Improve the Design of Future Trials in Sjögren’s Syndrome: Post Hoc Analysis from a Randomized Controlled Trial
jacques-eric gottenberg¹, Bryan Downie², Oksana Gurtovaya² and Anubhav Mathur², ¹Strasbourg University Hospital, Strasbourg, France, ²Gilead Sciences, Foster City, CA
Background/Purpose: A multicenter, global, randomized, Phase 2, double-blind, placebo (PBO)-controlled study showed filgotinib (FIL; 200 mg/d), lanraplenib (LAN; 30 mg/d), and tirabrutinib (TIRA; 40 mg/d)…
Abstract Number: 2052 • ACR Convergence 2022
Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) in a Large Urban Teaching Hospital Serving a High-Risk Population
J. Patricia Dhar¹, Forsythe Hannah², Louis Saravolatz³ and Susanna Szpunar⁴, ¹Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI, ²Michigan Department of Human and Health Services, Lansing, MI, ³Ascension St John Hospital and Medical Center, Wayne State University School of Medicine (affiliate), Grosse Pointe Woods, MI, ⁴Ascension St. John Hospital, Grosse Pointe Woods, MI
Background/Purpose: Infections are a major cause of morbidity & mortality in patients with systemic lupus erythematosus (SLE), including vaccine-preventable infections. SLE patients are considered to…
Abstract Number: 2056 • ACR Convergence 2022
Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis
Takehiro Nakai¹, Sho Fukui², Takahiro Asano³, Futoshi Iwata⁴, Hiroki Ozawa⁵, Satoshi Kawaai⁴, Yukihiko Ikeda¹, Hiromichi Tamaki¹, Mitsumasa Kishimoto⁶, Kenichi YAMAGUCHI⁷ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Kyorin University Hospital, Tokyo, Japan, ³St. Luke's International Hospital, Chuo City Tokyo, Japan, ⁴St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ⁵Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, ⁶Kyorin University School of Medicine, Yokohama, Japan, ⁷St.Luke's International Hospital, Tokyo, Japan
Background/Purpose: Many clinicians use belimumab as a maintenance therapy of SLE, but there is scarce data on belimumab drug retention rate and safety/effectiveness profile in…
Abstract Number: 2062 • ACR Convergence 2022
Predicting Severe Flares: Real-world Application of a Decision-Tree Model Among the Medicaid-Insured Systemic Lupus Erythematosus (SLE) Population in the US
Sandra Sze-jung Wu¹, Allison Perry², Nicole Zimmerman³, Helen Varker⁴, Rich Bizier⁴, Liisa Palmer⁴, Christine Dube⁵ and Gary Bryant⁶, ¹AstraZeneca, Hockessin, DE, ²IBM Watson Health, New York, NY, ³IBM Watson Health, Chagrin Falls, OH, ⁴Merative, Cambridge, MA, ⁵AstraZeneca, Torrington, CT, ⁶AstraZeneca, New Castle, DE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex disease with multisystem inflammation resulting in variable clinical manifestations. As a result, predicting the occurrence of an…
Abstract Number: 2066 • ACR Convergence 2022
Measuring Sexual Dysfunction as an Indicator of Frailty in Systemic Lupus Erythematosus Population
Daniela Marengo-Rodriguez¹, Astrid Hernandez-De La Torre¹, Maria Jose Chavez-Barajas¹, André Fortanell-Meza², Ana Barrera-Vargas², Diego San Agustin-Morales² and Javier Merayo-Chalico³, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico
Background/Purpose: Patients with SLE present with greater sexual dysfunction (SxD) than patients with other chronic diseases [1]. These patients tend to be younger compared to…
Abstract Number: 2061 • ACR Convergence 2022
Impact of Time to Remission, Flares and Exposure to Immunosuppressives on the Development of Advanced Chronic Kidney Disease (Stage IV or Worse) in Lupus Nephritis
Dafna Gladman¹, KONSTANTINOS TSELIOS², Jiandong Su³ and Murray Urowitz⁴, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²McMaster University, Population Health Research Institute, Hamilton, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) affects up to 40% of patients with SLE and leads to end stage kidney disease (ESKD) in 17-33% after 10 years.…
Abstract Number: 2063 • ACR Convergence 2022
Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus
Alfredo Aguirre¹, Kimberly DeQuattro², Patricia Katz³, Kurt Greenlund⁴, Kamil Barbour⁴, Caroline Gordon⁵, Cristina M Lanata⁶, Lindsey Criswell⁷, Maria Dall'Era⁸ and Jinoos Yazdany⁹, ¹University of California, San Francisco, San Francisco, CA, ²University of Pennsylvania, Philadelphia, PA, ³UCSF, San Rafael, CA, ⁴Centers for Disease Control and Prevention, Atlanta, GA, ⁵Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁶NIH/NHGRI, Washington, DC, ⁷National Human Genome Research Institute, NIH, Bethesda, MD, ⁸University of California, Division of Rheumatology, San Francisco, CA, ⁹UCSF, San Francisco, CA
Background/Purpose: Medication cost concerns are associated with nonadherence and poor outcomes in the general population. Prior research has described medication cost concerns in up to…
Abstract Number: 2065 • ACR Convergence 2022
Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares
Diane Zisa¹, Jeffrey Zhang-Sun¹, Paul Christos² and Kyriakos Kirou¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine/New York-Presbyterian, New York, NY
Background/Purpose: B cell targeting agents (BCA), including belimumab (BEL) and rituximab (RTX), have been used with success in lupus nephritis (LN) patients, though identifying patients…
Abstract Number: 2043 • ACR Convergence 2022
What Does Isolated Anti-Ro52 Antibody Positivity Mean in Sjögren’s Syndrome?
Eléonore Bettacchioli¹, Alain Saraux², Alice Tison³, Divi CORNEC⁴, Maryvonne Dueymes¹, Marta Alarcon-Riquelme⁵ and Valerie Devauchelle⁶, ¹Immunology and Immunotherapy Laboratory, CHRU Brest, Brest, France, ²CHU Brest, Brest, France, ³Rheumatology Department, CHRU Brest, Brest, France, ⁴CHRU Brest, Brest, France, ⁵Center for Genomics and Oncological Research (GENYO), Granada, Spain, ⁶Université de Bretagne Occidentale, Brest, France
Background/Purpose: Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterized by a triad of dryness, pain and fatigue in affected patients. Its diagnosis is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].